REGENXBIO Inc.
RGNX
$10.38
$1.7320.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.34M | 29.73M | 21.36M | 89.01M | 21.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.34M | 29.73M | 21.36M | 89.01M | 21.21M |
| Cost of Revenue | 65.54M | 61.83M | 64.71M | 56.52M | 56.70M |
| Gross Profit | -35.20M | -32.09M | -43.35M | 32.49M | -35.48M |
| SG&A Expenses | 22.38M | 20.25M | 19.88M | 20.35M | 15.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 54.00K | 65.00K | 45.00K | 15.00K | 833.00K |
| Total Operating Expenses | 87.97M | 82.14M | 84.64M | 76.89M | 72.58M |
| Operating Income | -57.64M | -52.41M | -63.28M | 12.13M | -51.37M |
| Income Before Tax | -67.15M | -61.94M | -70.87M | 6.08M | -51.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.15M | -61.94M | -70.87M | 6.08M | -51.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.15M | -61.94M | -70.87M | 6.08M | -51.19M |
| EBIT | -57.64M | -52.41M | -63.28M | 12.13M | -51.37M |
| EBITDA | -53.77M | -48.53M | -59.37M | 16.08M | -47.35M |
| EPS Basic | -1.30 | -1.20 | -1.38 | 0.12 | -1.01 |
| Normalized Basic EPS | -0.81 | -0.75 | -0.86 | 0.07 | -0.63 |
| EPS Diluted | -1.30 | -1.20 | -1.38 | 0.12 | -1.01 |
| Normalized Diluted EPS | -0.81 | -0.75 | -0.86 | 0.07 | -0.63 |
| Average Basic Shares Outstanding | 51.75M | 51.69M | 51.48M | 51.36M | 50.87M |
| Average Diluted Shares Outstanding | 51.75M | 51.69M | 51.48M | 51.43M | 50.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |